

Bruce L Wilkoff

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1871560/publications.pdf>

Version: 2024-02-01

347
papers

37,726
citations

7096

78
h-index

3034

188
g-index

349
all docs

349
docs citations

349
times ranked

22904
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk Factors for CIED Infection After Secondary Procedures. JACC: Clinical Electrophysiology, 2022, 8, 101-111.	3.2	20
2	Novel ventricular tachyarrhythmia detection enhancement detects undertreated life-threatening arrhythmias. Heart Rhythm O2, 2022, 3, 70-78.	1.7	6
3	Influence of “high” defibrillation thresholds on patient survival and impact of system modification. Journal of Cardiovascular Electrophysiology, 2022, 33, 234-240.	1.7	3
4	Innovative Approaches and Technology Platforms for Pacemaker Lead Extraction. , 2022, , 417-430.		0
5	Risk factors for hematoma in patients undergoing cardiac device procedures: A WRAP-IT trial analysis. Heart Rhythm O2, 2022, 3, 466-473.	1.7	3
6	Clinical Presentation, Timing, and Microbiology of CIED Infections. JACC: Clinical Electrophysiology, 2021, 7, 50-61.	3.2	11
7	Comparative Analysis of Procedural Outcomes and Complications Between De Novo and Upgraded Cardiac Resynchronization Therapy. JACC: Clinical Electrophysiology, 2021, 7, 62-72.	3.2	6
8	Predictors of permanent pacemaker requirement after cardiac surgery for infective endocarditis. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 329-334.	1.0	12
9	Long-Term Outcomes in Patients With a Left Ejection Fraction≤15% Undergoing Cardiac Resynchronization Therapy. JACC: Clinical Electrophysiology, 2021, 7, 36-46.	3.2	7
10	Exercise Ventricular Rates, Cardiopulmonary Exercise Performance, and Mortality in Patients With Heart Failure With Atrial Fibrillation. Circulation: Heart Failure, 2021, 14, e007451.	3.9	3
11	Implantable Cardioverter Defibrillator Lead Survival in Athletic Patients. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e009344.	4.8	3
12	Heart rate score, a measure related to chronotropic incompetence in pacemaker patients. Heart Rhythm O2, 2021, 2, 124-131.	1.7	8
13	Cardiac Resynchronization Therapy With or Without Defibrillation in Patients With Nonischemic Cardiomyopathy: A Systematic Review and Meta-Analysis. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e008991.	4.8	10
14	Infections associated with cardiac electronic implantable devices: economic perspectives and impact of the TYRX [®] antibacterial envelope. Europace, 2021, 23, iv33-iv44.	1.7	14
15	Antibiotic eluting envelopes: evidence, technology, and defining high-risk populations. Europace, 2021, 23, iv28-iv32.	1.7	6
16	Infectious consequences of hematoma from cardiac implantable electronic device procedures and the role of the antibiotic envelope: A WRAP-IT trial analysis. Heart Rhythm, 2021, 18, 2080-2086.	0.7	19
17	Cost-Effectiveness Analyses of an Absorbable Antibacterial Envelope for Use in Patients at Increased Risk of Cardiac Implantable Electronic Device Infection in Germany, Italy, and England. Value in Health, 2021, 24, 930-938.	0.3	19
18	Lower rate limit for pacing by cardiac resynchronization defibrillators: Should lower rate programming be reconsidered?. Heart Rhythm, 2021, 18, 2087-2093.	0.7	4

#	ARTICLE	IF	CITATIONS
19	InÂvitro modeling accurately predicts cardiac lead fracture at 10 years. Heart Rhythm, 2021, 18, 1605-1612.	0.7	6
20	2021: The American Association for Thoracic Surgery Expert Consensus Document: Coronary artery bypass grafting in patients with ischemic cardiomyopathy and heart failure. Journal of Thoracic and Cardiovascular Surgery, 2021, 162, 829-850.e1.	0.8	34
21	Predictors of Cardiac Implantable Electronic Device Artifact on Cardiac MRI: The Utility of a Device Related Score. Heart Lung and Circulation, 2021, 30, 1348-1355.	0.4	3
22	Cardiac resynchronisation therapy in anthracycline-induced cardiomyopathy. Heart, 2021, , heartjnl-2020-318333.	2.9	3
23	2019 HRS/EHRA/APHRS/LAHRs focused update to 2015 expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. Heart Rhythm, 2020, 17, e220-e228.	0.7	55
24	Rapid ventricular pacing during transcatheter valve procedures using an internal device and programmer: A demonstration of feasibility. Catheterization and Cardiovascular Interventions, 2020, 95, 1042-1048.	1.7	5
25	Heart rate score predicts mortality independent of shocks in ICD and CRT-D patients. Journal of Interventional Cardiac Electrophysiology, 2020, 58, 103-111.	1.3	0
26	Baseline Right Ventricular Dysfunction Predicts Worse Outcomes in Patients Undergoing Cardiac Resynchronization Therapy Implantation. Journal of Cardiac Failure, 2020, 26, 227-232.	1.7	8
27	The gap between what patients know and desire to learn about their cardiac implantable electronic devices. PACE - Pacing and Clinical Electrophysiology, 2020, 43, 118-122.	1.2	8
28	Cost-Effectiveness of an Antibacterial Envelope for Cardiac Implantable Electronic Device Infection Prevention in the US Healthcare System From the WRAP-IT Trial. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008503.	4.8	39
29	Obesity Predicts Survival After Cardiac Resynchronization Therapy Independent of Effect on Left Ventricular Ejection Fraction. Circulation: Heart Failure, 2020, 13, e007424.	3.9	1
30	Economic implications of adding a novel algorithm to optimize cardiac resynchronization therapy: rationale and design of economic analysis for the AdaptResponse trial. Journal of Medical Economics, 2020, 23, 1401-1408.	2.1	1
31	Differences in clinical characteristics and reported quality of life of men and women undergoing cardiac resynchronization therapy. ESC Heart Failure, 2020, 7, 2972-2982.	3.1	9
32	Proarrhythmic effects from competitive atrial pacing and potential programming solutions. PACE - Pacing and Clinical Electrophysiology, 2020, 43, 720-729.	1.2	4
33	Transvenous lead extraction in patients with prior extraction procedures: Procedural profiles and outcomes. Heart Rhythm, 2020, 17, 1904-1908.	0.7	2
34	Clinical Outcomes and Characteristics With Dofetilide in Atrial Fibrillation Patients Considered for Implantable Cardioverter-Defibrillator. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008168.	4.8	3
35	Predictors of long-term outcomes greater than 10 years after cardiac resynchronization therapy implantation. Journal of Cardiovascular Electrophysiology, 2020, 31, 1182-1186.	1.7	6
36	The World-wide Randomized Antibiotic Envelope Infection Prevention (WRAP-IT) trial: Long-term follow-up. Heart Rhythm, 2020, 17, 1115-1122.	0.7	42

#	ARTICLE	IF	CITATIONS
37	Impact of Cardiac Implantable Electronic Device Infection. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008280.	4.8	41
38	Cardiac venous injuries: Procedural profiles and outcomes during left ventricular lead placement for cardiac resynchronization therapy. Heart Rhythm, 2020, 17, 1298-1303.	0.7	10
39	Use of virtual visits for the care of the arrhythmia patient. Heart Rhythm, 2020, 17, 1779-1783.	0.7	18
40	Cautery selection for oculofacial plastic surgery in patients with implantable electronic devices. European Journal of Ophthalmology, 2019, 29, 315-322.	1.3	3
41	Conversion, Compromise, and Conversation—Moving to a Sensible Middle When Addressing Implantable Cardioverter-Defibrillator Therapy. JAMA Cardiology, 2019, 4, 1049.	6.1	0
42	Endovascular Occlusion Balloon for Treatment of Superior Vena Cava Tears During Transvenous Lead Extraction. Circulation: Arrhythmia and Electrophysiology, 2019, 12, e007266.	4.8	31
43	Cardiac Implantable Electronic Device Therapy in Heart Failure. Circulation Research, 2019, 124, 1584-1597.	4.5	37
44	Long term outcomes in patients with chronic right ventricular pacing upgraded to cardiac resynchronization therapy. Journal of Cardiovascular Electrophysiology, 2019, 30, 1979-1983.	1.7	2
45	Antibacterial Envelope to Prevent Cardiac Implantable Device Infection. New England Journal of Medicine, 2019, 380, 1895-1905.	27.0	251
46	Hypothermia Outcomes After Transvenous Lead Extraction Complications Requiring Cardiothoracic Surgery. Circulation: Arrhythmia and Electrophysiology, 2019, 12, e007831.	4.8	0
47	Lead Location as Assessed on Cardiac Computed Tomography and Difficulty of Percutaneous Transvenous Extraction. JACC: Clinical Electrophysiology, 2019, 5, 1432-1438.	3.2	18
48	Effect of Cardiac Resynchronization Therapy on Left Ventricular Remodeling in Patients With Cardiac Sarcoidosis. American Journal of Cardiology, 2019, 123, 329-333.	1.6	17
49	Competitive athletes with implantable cardioverter-defibrillators—How to program? Data from the Implantable Cardioverter-Defibrillator Sports Registry. Heart Rhythm, 2019, 16, 581-587.	0.7	27
50	Superior vena cava reconstruction and implantation of a leadless pacemaker for management of pacemaker-induced superior vena cava syndrome. Heart Rhythm Case Reports, 2019, 5, 539-541.	0.4	2
51	Transvenous Lead Extraction: A Clinical Commentary for Anesthesiologists. Journal of Cardiothoracic and Vascular Anesthesia, 2018, 32, 1101-1111.	1.3	5
52	Dofetilide for suppression of atrial fibrillation in hypertrophic cardiomyopathy: A case series and literature review. PACE - Pacing and Clinical Electrophysiology, 2018, 41, 396-401.	1.2	23
53	Unrecognized venous injuries after cardiac implantable electronic device transvenous lead extraction. Heart Rhythm, 2018, 15, 318-325.	0.7	15
54	Transvenous Lead Extraction in Chronic Kidney Disease and Dialysis Patients With Infected Cardiac Devices. Circulation: Arrhythmia and Electrophysiology, 2018, 11, e005706.	4.8	17

#	ARTICLE	IF	CITATIONS
55	Implantable Cardioverter Defibrillators. , 2018, , 1101-1112.		0
56	Lead Management for Electrophysiologists. Cardiac Electrophysiology Clinics, 2018, 10, xiii-xiv.	1.7	0
57	Nomenclature, Definitions, and Metrics of Cardiovascular Implantable Electronic Device Lead Management. Cardiac Electrophysiology Clinics, 2018, 10, 609-613.	1.7	1
58	Overview of Lead Management. Cardiac Electrophysiology Clinics, 2018, 10, 549-559.	1.7	0
59	Transvenous Extraction of Pacemaker and Defibrillator Leads and the Risk of Tricuspid Valve Regurgitation. JACC: Clinical Electrophysiology, 2018, 4, 1421-1428.	3.2	42
60	Advances in cardiac implantable electronic device infection prevention: should we push the envelope?. Future Cardiology, 2018, 14, 359-366.	1.2	4
61	Removal of subcutaneous defibrillator shocking coils: Lessons to learn for future extraction of subcutaneous defibrillator systems. PACE - Pacing and Clinical Electrophysiology, 2018, 41, 1341-1344.	1.2	6
62	Single vs. dual chamber implantable cardioverter-defibrillators or programming of implantable cardioverter-defibrillators in patients without a bradycardia pacing indication: systematic review and meta-analysis. Europace, 2018, 20, 1621-1629.	1.7	20
63	Addition of minute ventilation to rate-response pacing improves heart rate score more than accelerometer alone. Heart Rhythm, 2018, 15, 1730-1735.	0.7	6
64	Incidence, indications, risk factors, and survival of patients undergoing cardiac implantable electronic device implantation after open heart surgery. Europace, 2017, 19, euw234.	1.7	21
65	A Device Histogram-Based Simple Predictor of Mortality Risk in ICD and CRT Patients: The Heart Rate Score. PACE - Pacing and Clinical Electrophysiology, 2017, 40, 333-343.	1.2	16
66	Left Ventricular Size does not Modify the Effect of QRS Duration in Predicting Response to Cardiac Resynchronization Therapy. PACE - Pacing and Clinical Electrophysiology, 2017, 40, 482-487.	1.2	10
67	Echocardiographic Predictors of Long-Term Survival in Patients Undergoing Cardiac Resynchronization Therapy: What Is the Optimal Metric?. Journal of Cardiovascular Electrophysiology, 2017, 28, 410-415.	1.7	19
68	2017 HRS expert consensus statement on magnetic resonance imaging and radiation exposure in patients with cardiovascular implantable electronic devices. Heart Rhythm, 2017, 14, e97-e153.	0.7	308
69	Compliant endovascular balloon reduces the lethality of superior vena cava tears during transvenous lead extractions. Heart Rhythm, 2017, 14, 1400-1404.	0.7	42
70	Safety of Oral Dofetilide Reloading for Treatment of Atrial Arrhythmias. Circulation: Arrhythmia and Electrophysiology, 2017, 10, .	4.8	12
71	Transvenous lead extraction at the time of cardiac implantable electronic device upgrade: Complexity, safety, and outcomes. Heart Rhythm, 2017, 14, 1807-1811.	0.7	26
72	2017 HRS expert consensus statement on cardiovascular implantable electronic device lead management and extraction. Heart Rhythm, 2017, 14, e503-e551.	0.7	792

#	ARTICLE	IF	CITATIONS
73	Effect of PR interval prolongation on long-term outcomes in patients with left bundle branch block vs non-“left bundle branch block morphologies undergoing cardiac resynchronization therapy. Heart Rhythm, 2017, 14, 1523-1528.	0.7	17
74	Bridge to surgery: Best practice protocol derived from early clinical experience with the Bridge Occlusion Balloon. Federated Agreement from the Eleventh Annual Lead Management Symposium. Heart Rhythm, 2017, 14, 1574-1578.	0.7	41
75	Incidence and predictors of late atrioventricular conduction recovery among patients requiring permanent pacemaker for complete heart block after cardiac surgery. Heart Rhythm, 2017, 14, 1786-1792.	0.7	21
76	Lead Extraction Considerations for the Referring Cardiologist. Cardiology in Review, 2017, 25, 17-21.	1.4	2
77	Bridging the gap between heart failure and the device clinic. Expert Review of Medical Devices, 2017, 14, 601-607.	2.8	0
78	Lead Removal and Extraction. , 2017, , 937-958.		2
79	Coronary Sinus Lead Extraction. Heart Failure Clinics, 2017, 13, 105-115.	2.1	5
80	Cardiac Implantable Electronic Device-“Infections. JACC: Clinical Electrophysiology, 2017, 3, 1-9.	3.2	54
81	Establishing and Managing a Device Clinic and Database. , 2017, , 1191-1200.		0
82	Safety of Sports for Athletes With Implantable Cardioverter-Defibrillators. Circulation, 2017, 135, 2310-2312.	1.6	107
83	Abstract 23072: Unrecognized Venous Injuries After Cardiac Implantable Electronic Device Transvenous Lead Extraction. Circulation, 2017, 136, .	1.6	0
84	The biostability of cardiac lead insulation materials as assessed from long-term human implants. Journal of Biomedical Materials Research - Part B Applied Biomaterials, 2016, 104, 411-421.	3.4	26
85	2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-“defibrillator programming and testing. Journal of Arrhythmia, 2016, 32, 1-28.	1.2	34
86	Microbiology of Cardiac Implantable Electronic Device Infections. JACC: Clinical Electrophysiology, 2016, 2, 498-505.	3.2	79
87	Worldwide Randomized Antibiotic EnveloPe Infection PrevenTion Trial (WRAP-IT). American Heart Journal, 2016, 180, 12-21.	2.7	53
88	Survival After Rate-Responsive Programming in Patients With Cardiac Resynchronization Therapy-Defibrillator Implants Is Associated With a Novel Parameter. Circulation: Arrhythmia and Electrophysiology, 2016, 9, .	4.8	23
89	Incidence and predictors of right ventricular pacing-induced cardiomyopathy in patients with complete atrioventricular block and preserved left ventricular systolic function. Heart Rhythm, 2016, 13, 2272-2278.	0.7	285
90	2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. Heart Rhythm, 2016, 13, e50-e86.	0.7	197

#	ARTICLE	IF	CITATIONS
91	Extracción de electrodos transvenosos de dispositivos electrónicos implantables cardiacos: ¿quién, cuándo, cómo y dónde?. Revista Espanola De Cardiologia, 2016, 69, 3-6.	1.2	13
92	Considerations for cardiac device lead extraction. Nature Reviews Cardiology, 2016, 13, 221-229.	13.7	47
93	Cardiac Resynchronization Therapy. Circulation: Arrhythmia and Electrophysiology, 2016, 9, e003108.	4.8	47
94	Advances in implantable cardioverter defibrillator therapy. Expert Review of Cardiovascular Therapy, 2016, 14, 291-299.	1.5	2
95	Transvenous Lead Extraction of Cardiac Implantable Electronic Devices: Who, When, How and Where?. Revista Espanola De Cardiologia (English Ed), 2016, 69, 3-6.	0.6	3
96	2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. Europace, 2016, 18, 159-183.	1.7	135
97	Successful stent implantation for superior vena cava injury during transvenous lead extraction. HeartRhythm Case Reports, 2015, 1, 394-396.	0.4	10
98	Strain-time curve analysis by speckle tracking echocardiography in cardiac resynchronization therapy: Insight into the pathophysiology of responders vs. non-responders. Cardiovascular Ultrasound, 2015, 14, 14.	1.6	10
99	Interruption of Pacing Following Nonsustained Ventricular Tachycardia in an AAI Programmed Implantable Cardioverter Defibrillator. PACE - Pacing and Clinical Electrophysiology, 2015, 38, 1082-1090.	1.2	1
100	Antitachycardia pacing for reduction of implantable cardioverter-defibrillator shocks. Heart Rhythm, 2015, 12, 1370-1375.	0.7	15
101	Standardized MR Terminology and Reporting of Implants and Devices as Recommended by the American College of Radiology Subcommittee on MR Safety. Radiology, 2015, 274, 866-870.	7.3	19
102	Noninvasive Mapping of Electrical Dyssynchrony in Heart Failure and Cardiac Resynchronization Therapy. Cardiac Electrophysiology Clinics, 2015, 7, 125-134.	1.7	20
103	Using a novel wireless system for monitoring patients after the atrial fibrillation ablation procedure: The iTransmit study. Heart Rhythm, 2015, 12, 554-559.	0.7	125
104	Reverse ventricular remodeling and long-term survival in patients undergoing cardiac resynchronization with surgically versus percutaneously placed left ventricular pacing leads. Heart Rhythm, 2015, 12, 517-523.	0.7	20
105	Comparison of Left Ventricular Torsion and Strain With Biventricular Pacing in Patients With Underlying Right Bundle Branch Block Versus Those With Left Bundle Branch Block. American Journal of Cardiology, 2015, 115, 918-923.	1.6	4
106	Pacemaker implantation in pediatric heart transplant recipients: Predictors, outcomes, and impact on survival. Heart Rhythm, 2015, 12, 1776-1781.	0.7	18
107	Catheter Ablation for Atrial Fibrillation in Heart Failure Patients. JACC: Clinical Electrophysiology, 2015, 1, 200-209.	3.2	86
108	Safety of Oral Dofetilide for Rhythm Control of Atrial Fibrillation and Atrial Flutter. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 772-776.	4.8	60

#	ARTICLE	IF	CITATIONS
109	Electrical dyssynchrony induced by biventricular pacing: Implications for patient selection and therapy improvement. Heart Rhythm, 2015, 12, 782-791.	0.7	100
110	Nomogram for predicting 30-day all-cause mortality after transvenous pacemaker and defibrillator lead extraction. Heart Rhythm, 2015, 12, 2381-2386.	0.7	50
111	The Impact of Changing Antiseptic Skin Preparation Agent used for Cardiac Implantable Electronic Device (CIED) Procedures on the Risk of Infection. PACE - Pacing and Clinical Electrophysiology, 2015, 38, 240-246.	1.2	28
112	Comparative Efficacy of Cardiac Resynchronization Therapy in Africans Americans Compared With European Americans. American Journal of Cardiology, 2015, 116, 1101-1105.	1.6	2
113	Coronary Sinus Lead Extraction. Cardiac Electrophysiology Clinics, 2015, 7, 661-671.	1.7	6
114	Implantable Cardioverter-Defibrillators in Patients with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1119-1127.	4.5	29
115	Long-Term Outcomes in Patients With Ambulatory New York Heart Association Class III and IV Heart Failure Undergoing Cardiac Resynchronization Therapy. American Journal of Cardiology, 2015, 115, 82-85.	1.6	15
116	Implantable Cardioverter Defibrillators. , 2014, , 1139-1150.		1
117	Prospective long-term evaluation of Optim-insulated (Riata ST Optim and Durata) implantable cardioverter-defibrillator leads. Heart Rhythm, 2014, 11, 2156-2162.	0.7	28
118	Risk factors for 1-year mortality among patients with cardiac implantable electronic device infection undergoing transvenous lead extraction: the impact of the infection type and the presence of vegetation on survival. Europace, 2014, 16, 1490-1495.	1.7	151
119	Survival in Octogenarians Undergoing Cardiac Resynchronization Therapy Compared to the General Population. PACE - Pacing and Clinical Electrophysiology, 2014, 37, 740-744.	1.2	13
120	A Clinical Prediction Rule to Identify Patients at Heightened Risk for Early Demise Following Cardiac Resynchronization Therapy. Journal of Cardiovascular Electrophysiology, 2014, 25, 278-282.	1.7	5
121	The Epidemic of Inadequate Biventricular Pacing in Patients With Persistent or Permanent Atrial Fibrillation and Its Association With Mortality. Circulation: Arrhythmia and Electrophysiology, 2014, 7, 370-376.	4.8	66
122	Conductor externalization of the Biotronik Kentrox internal cardioverter-defibrillator lead: The tip of another iceberg?. Heart Rhythm, 2014, 11, 1648-1650.	0.7	9
123	Outcomes of patients requiring emergent surgical or endovascular intervention for catastrophic complications during transvenous lead extraction. Heart Rhythm, 2014, 11, 419-425.	0.7	137
124	Incidence, management, and outcomes of the arteriovenous fistula complicating transvenous lead extraction. Heart Rhythm, 2014, 11, 404-411.	0.7	16
125	Clinical predictors of adverse patient outcomes in an experience of more than 5000 chronic endovascular pacemaker and defibrillator lead extractions. Heart Rhythm, 2014, 11, 799-805.	0.7	183
126	Cardiac Implantable Electronic Device Infections: Facts, Current Practice, and the Unanswered Questions. Current Infectious Disease Reports, 2014, 16, 425.	3.0	12

#	ARTICLE	IF	CITATIONS
127	Cardiac resynchronization therapy for exercise-induced left ventricular dysfunction in the setting of left bundle branch block: A case report and review of the literature. <i>Journal of Arrhythmia</i> , 2014, 30, 519-521.	1.2	0
128	Shock Avoidance and the Newer Tachycardia Therapy Algorithms. <i>Cardiology Clinics</i> , 2014, 32, 191-200.	2.2	4
129	Durability of the survival effect of cardiac resynchronization therapy by level of left ventricular functional improvement: Fate of "nonresponders". <i>Heart Rhythm</i> , 2014, 11, 412-416.	0.7	45
130	Short- and long-term electrical performance of the 5086MRI pacing lead. <i>Heart Rhythm</i> , 2014, 11, 222-229.	0.7	21
131	Low cardiac output associated with ventricular tachyarrhythmias in continuous-flow LVAD recipients with a concomitant ICD (LoCo VT Study). <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, 318-320.	0.6	29
132	Multicenter experience with extraction of the Riata/Riata ST ICD lead. <i>Heart Rhythm</i> , 2014, 11, 1613-1618.	0.7	45
133	2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1495-1539.	2.8	276
134	Follow-up of patients with new cardiovascular implantable electronic devices: Is adherence to the experts' recommendations associated with improved outcomes?. <i>Heart Rhythm</i> , 2013, 10, 1127-1133.	0.7	18
135	Survival of Patients With Biventricular Devices After Device Infection, Extraction, and Reimplantation. <i>JACC: Heart Failure</i> , 2013, 1, 508-513.	4.1	21
136	Safe magnetic resonance imaging scanning of patients with cardiac rhythm devices: A role for computer modeling. <i>Heart Rhythm</i> , 2013, 10, 1815-1821.	0.7	51
137	The National ICD Registry Report: Version 2.1 including leads and pediatrics for years 2010 and 2011. <i>Heart Rhythm</i> , 2013, 10, e59-e65.	0.7	181
138	2013 ACCF/AHA Guideline for the Management of Heart Failure. <i>Circulation</i> , 2013, 128, e240-327.	1.6	2,335
139	Transvenous extraction of implantable cardioverter-defibrillator leads under advisory: A comparison of Riata, Sprint Fidelis, and non-recalled implantable cardioverter-defibrillator leads. <i>Heart Rhythm</i> , 2013, 10, 1444-1450.	0.7	59
140	Noninvasive Electrocardiographic Mapping to Improve Patient Selection for Cardiac Resynchronization Therapy. <i>Journal of the American College of Cardiology</i> , 2013, 61, 2435-2443.	2.8	178
141	QRS narrowing is associated with reverse remodeling in patients with chronic right ventricular pacing upgraded to cardiac resynchronization therapy. <i>Heart Rhythm</i> , 2013, 10, 55-60.	0.7	43
142	How to diagnose and manage patients with cardiac implantable electronic device infections. <i>Journal of Arrhythmia</i> , 2013, 29, 320-324.	1.2	2
143	Role of CMR Imaging in Risk Stratification for Sudden Cardiac Death. <i>JACC: Cardiovascular Imaging</i> , 2013, 6, 392-406.	5.3	64
144	Understanding lead dysfunction: Managing lead failure grief. <i>Heart Rhythm</i> , 2013, 10, 1460-1461.	0.7	1

#	ARTICLE	IF	CITATIONS
145	Superior Vena Cava Defibrillator Coils Make Transvenous Lead Extraction More Challenging and Riskier. Journal of the American College of Cardiology, 2013, 61, 987-989.	2.8	421
146	2013 ACCF/AHA Guideline for the Management of Heart Failure. Journal of the American College of Cardiology, 2013, 62, e147-e239.	2.8	7,017
147	Management of cardiac implantable electronic device infections: the challenges of understanding the scope of the problem and its associated mortality. Expert Review of Cardiovascular Therapy, 2013, 11, 607-616.	1.5	25
148	Safety of Sports for Athletes With Implantable Cardioverter-Defibrillators. Circulation, 2013, 127, 2021-2030.	1.6	209
149	Follow-up of Patients With New Cardiovascular Implantable Electronic Devices. Circulation: Arrhythmia and Electrophysiology, 2013, 6, 108-116.	4.8	38
150	2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary. Circulation, 2013, 128, 1810-1852.	1.6	2,807
151	ACR guidance document on MR safe practices: 2013. Journal of Magnetic Resonance Imaging, 2013, 37, 501-530.	3.4	582
152	Clinical Experience and Procedural Outcomes Associated with the DF4 Implantable Cardioverter Defibrillator System: The SJ4 Postapproval Study. PACE - Pacing and Clinical Electrophysiology, 2013, 36, 855-862.	1.2	7
153	Safety of repetitive nerve stimulation in patients with cardiac implantable electronic devices. Muscle and Nerve, 2013, 47, 840-844.	2.2	16
154	Cost efficiency and reimbursement of remote monitoring: a US perspective. Europace, 2013, 15, i54-i58.	1.7	14
155	The Implantable Cardioverter Defibrillator: Technical and Clinical Considerations. , 2013, , 611-620.		0
156	Impact of Mitral Regurgitation on Reverse Remodeling and Outcome in Patients Undergoing Cardiac Resynchronization Therapy. Circulation: Cardiovascular Imaging, 2012, 5, 21-26.	2.6	52
157	Improved Programming of ICDs. New England Journal of Medicine, 2012, 367, 2348-2349.	27.0	4
158	Magnetic Resonance Imaging Conditional Pacemakers: Rationale, Development and Future Directions. Indian Pacing and Electrophysiology Journal, 2012, 12, 204-212.	0.6	15
159	Cardiac Venous Left Ventricular Lead Removal and Reimplantation Following Device Infection: A Large Single-Center Experience. Journal of Cardiovascular Electrophysiology, 2012, 23, 1213-1216.	1.7	26
160	CRT or CRT-D devices? The case for "high energy" devices. Heart Failure Reviews, 2012, 17, 777-779.	3.9	0
161	QRS prolongation induced by cardiac resynchronization therapy correlates with deterioration in left ventricular function. Heart Rhythm, 2012, 9, 1674-1678.	0.7	27
162	The impact of atrial fibrillation with rapid ventricular rates and device programming on shocks in 106,513 ICD and CRT-D patients. Heart Rhythm, 2012, 9, 24-31.	0.7	54

#	ARTICLE	IF	CITATIONS
163	Every life counts. Heart Rhythm, 2012, 9, 1239-1240.	0.7	0
164	Remote monitoring of cardiovascular devices: a time and activity analysis. Heart Rhythm, 2012, 9, 1947-1951.	0.7	89
165	2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management: A registered branch of the European Society of Cardiology (ESC), and the Heart Rhythm Society; and in collaboration with the Heart Failure Society of America (HFSA), the American Society of Echocardiography (ASE), the American Heart Association (AHA), the European Association of Echocardiography (EAE) of the ESC and the Heart		

#	ARTICLE	IF	CITATIONS
181	Prevention and Management of Procedural Complications. , 2011, , 741-746.		0
182	Fibrotic Tissue Growth into the Extendable Lobes of an Active Fixation Coronary Sinus Lead Can Complicate Extraction. PACE - Pacing and Clinical Electrophysiology, 2011, 34, e64-5.	1.2	14
183	The QRS Narrowing Index Predicts Reverse Left Ventricular Remodeling Following Cardiac Resynchronization Therapy. PACE - Pacing and Clinical Electrophysiology, 2011, 34, 604-611.	1.2	62
184	Prognostic Significance of Atrial Arrhythmias in a Primary Prevention ICD Population. PACE - Pacing and Clinical Electrophysiology, 2011, 34, 1070-1079.	1.2	16
185	QRS Fragmentation Is Not Associated with Poor Response to Cardiac Resynchronization Therapy. Annals of Noninvasive Electrocardiology, 2011, 16, 165-171.	1.1	17
186	Continuous Hemodynamic Monitoring in Patients With Mild to Moderate Heart Failure: Results of the Reducing Decompensation Events Utilizing Intracardiac Pressures in Patients With Chronic Heart Failure (REDUCEhf) Trial. Congestive Heart Failure, 2011, 17, 248-254.	2.0	79
187	Predictors of Response to Cardiac Resynchronization Therapy in Patients With a Non-Left Bundle Branch Block Morphology. American Journal of Cardiology, 2011, 108, 1576-1580.	1.6	45
188	Catheter Ablation for Atrial Fibrillation. New England Journal of Medicine, 2011, 365, 2296-2304.	27.0	82
189	Chest radiography is a poor predictor of left ventricular lead position in patients undergoing cardiac resynchronization therapy: comparison with multidetector computed tomography. Journal of Interventional Cardiac Electrophysiology, 2011, 32, 59-65.	1.3	16
190	Design and Rationale of the Assessment of Proper Physiologic Response with Rate Adaptive Pacing Driven by Minute Ventilation or Accelerometer (APPROPRIATE) Trial. Journal of Cardiovascular Translational Research, 2011, 4, 21-26.	2.4	6
191	Extraction of Implantable Cardiac Electronic Devices. Current Cardiology Reports, 2011, 13, 407-414.	2.9	22
192	Staphylococcus aureus Bacteremia and Endocarditis. Infectious Diseases in Clinical Practice, 2011, 19, 376-381.	0.3	1
193	Techniques and Devices for Lead Extraction. , 2011, , 747-770.		0
194	Device Therapy in Heart Failure. , 2011, , 694-703.		0
195	Infections associated with cardiac implantable electronic devices are misunderstood. Texas Heart Institute Journal, 2011, 38, 353-4.	0.3	6
196	Cardiac Resynchronization Therapy in Non-Left Bundle Branch Block Morphologies. PACE - Pacing and Clinical Electrophysiology, 2010, 33, 590-595.	1.2	59
197	Usefulness of Cardiac Resynchronization Therapy in Patients With Adriamycin-Induced Cardiomyopathy. American Journal of Cardiology, 2010, 105, 522-526.	1.6	50
198	Insights From Internet-Based Remote Intrathoracic Impedance Monitoring as Part of a Heart Failure Disease Management Program. Congestive Heart Failure, 2010, 16, 159-163.	2.0	16

#	ARTICLE	IF	CITATIONS
199	Strategic choices to reduce implantable cardioverter-defibrillator-related morbidity. <i>Nature Reviews Cardiology</i> , 2010, 7, 376-383.	13.7	9
200	Effectiveness of implantable cardioverter-defibrillator lead coil treatments in facilitating ease of extraction. <i>Heart Rhythm</i> , 2010, 7, 890-897.	0.7	23
201	Initial experience with the Evolution mechanical dilator sheath for lead extraction: Safety and efficacy. <i>Heart Rhythm</i> , 2010, 7, 870-873.	0.7	67
202	Improved survival among ventricular assist device recipients with a concomitant implantable cardioverter-defibrillator. <i>Heart Rhythm</i> , 2010, 7, 466-471.	0.7	120
203	Differences in effects of electrical therapy type for ventricular arrhythmias on mortality in implantable cardioverter-defibrillator patients. <i>Heart Rhythm</i> , 2010, 7, 353-360.	0.7	307
204	A Heart Rhythm Society Electrophysiology Workforce Study: Current survey analysis of physician workforce trends. <i>Heart Rhythm</i> , 2010, 7, 1346-1355.	0.7	20
205	Cardiac implantable electronic device infections: Presentation, management, and patient outcomes. <i>Heart Rhythm</i> , 2010, 7, 1043-1047.	0.7	242
206	Characterization of super-response to cardiac resynchronization therapy. <i>Heart Rhythm</i> , 2010, 7, 885-889.	0.7	91
207	Lead Extraction in the Contemporary Setting: The LEXIcon Study. <i>Journal of the American College of Cardiology</i> , 2010, 55, 579-586.	2.8	503
208	Long-Term Reverse Remodeling With Cardiac Resynchronization Therapy. <i>Journal of the American College of Cardiology</i> , 2010, 55, 1788-1795.	2.8	78
209	Long-term outcomes and clinical predictors for pacemaker-requiring bradyarrhythmias after cardiac transplantation: Analysis of the UNOS/OPTN cardiac transplant database. <i>Heart Rhythm</i> , 2010, 7, 1567-1571.	0.7	71
210	Shorter AV Delays Provide Improved Echocardiographic Hemodynamics during Exercise in Patients Receiving Cardiac Resynchronization Therapy. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2009, 32, 457-465.	1.2	13
211	The Impact of Myocardial Viability on the Clinical Outcome of Cardiac Resynchronization Therapy. <i>Journal of Cardiovascular Electrophysiology</i> , 2009, 20, 50-57.	1.7	40
212	Long-term Outcomes and Clinical Predictors for Pacing After Cardiac Transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2009, 28, 791-798.	0.6	27
213	Persistent Hemodynamic Benefits of Cardiac Resynchronization Therapy With Disease Progression in Advanced Heart Failure. <i>Journal of the American College of Cardiology</i> , 2009, 53, 600-607.	2.8	65
214	The DAVID (Dual Chamber and VVI Implantable Defibrillator) II Trial. <i>Journal of the American College of Cardiology</i> , 2009, 53, 872-880.	2.8	89
215	Insights From a Cardiac Resynchronization Optimization Clinic as Part of a Heart Failure Disease Management Program. <i>Journal of the American College of Cardiology</i> , 2009, 53, 765-773.	2.8	424
216	Clinical Benefits of Remote Versus Transtelephonic Monitoring of Implanted Pacemakers. <i>Journal of the American College of Cardiology</i> , 2009, 54, 2012-2019.	2.8	187

#	ARTICLE	IF	CITATIONS
217	Recommendations from the Heart Rhythm Society Task Force on Lead Performance Policies and Guidelines. Heart Rhythm, 2009, 6, 869-885.	0.7	107
218	Transiliac ICD implantation: Defibrillation vector flexibility produces consistent success. Heart Rhythm, 2009, 6, 978-983.	0.7	20
219	Transvenous Lead Extraction: Heart Rhythm Society Expert Consensus on Facilities, Training, Indications, and Patient Management. Heart Rhythm, 2009, 6, 1085-1104.	0.7	929
220	Heart rate, pacing, and outcome in the Dual Chamber and VVI Implantable Defibrillator (DAVID) trials. Heart Rhythm, 2009, 6, 1129-1135.	0.7	5
221	Pacemaker and ICD leads: Strategies for long-term management. Journal of Interventional Cardiac Electrophysiology, 2008, 23, 59-72.	1.3	63
222	Design of the Pacemaker Remote Follow-up Evaluation and Review (PREFER) trial to assess the clinical value of the remote pacemaker interrogation in the management of pacemaker patients. Trials, 2008, 9, 18.	1.6	20
223	Safety of magnetic resonance imaging of patients with a new Medtronic EnRhythm MRI SureScan pacing system: clinical study design. Trials, 2008, 9, 68.	1.6	87
224	Hypersensitivity reactions associated with endovascular devices. Contact Dermatitis, 2008, 59, 7-22.	1.4	122
225	Effect of Pacing for Soft Indications on Mortality and Heart Failure in the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. PACE - Pacing and Clinical Electrophysiology, 2008, 31, 828-837.	1.2	23
226	Mortality of Heart Failure Patients After Cardiac Resynchronization Therapy: Identification of Predictors. Journal of Cardiovascular Electrophysiology, 2008, 19, 1259-1265.	1.7	60
227	Prognostic Value of Electrocardiographic Measurements Before and After Cardiac Resynchronization Device Implantation in Patients With Heart Failure due to Ischemic or Nonischemic Cardiomyopathy. American Journal of Cardiology, 2008, 101, 359-363.	1.6	43
228	Remote Cardiac Monitoring in Patients With Heart Failure. Congestive Heart Failure, 2008, 14, 4-6.	2.0	2
229	Strategic Programming of Detection and Therapy Parameters in Implantable Cardioverter-Defibrillators Reduces Shocks in Primary Prevention Patients. Journal of the American College of Cardiology, 2008, 52, 541-550.	2.8	504
230	HRS/EHRA Expert Consensus on the Monitoring of Cardiovascular Implantable Electronic Devices (CIEDs): Description of Techniques, Indications, Personnel, Frequency and Ethical Considerations. Heart Rhythm, 2008, 5, 907-925.	0.7	279
231	HRS/EHRA Expert Consensus on the Monitoring of Cardiovascular Implantable Electronic Devices (CIEDs): Description of Techniques, Indications, Personnel, Frequency and Ethical Considerations: Developed in partnership with the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA); and in collaboration with the American College of Cardiology (ACC), the American Heart Association (AHA), the European Society of Cardiology (ESC), the Heart Failure Association of ESC (HFA), and the Heart Fail. Europace, 2008, 10, 707-725.	1.7	215
232	The magnitude of reverse remodelling irrespective of aetiology predicts outcome of heart failure patients treated with cardiac resynchronization therapy. European Heart Journal, 2008, 29, 2497-2505.	2.2	44
233	Interventional Electrophysiology and Cardiac Resynchronization Therapy. Circulation, 2007, 115, 2208-2220.	1.6	39
234	How to treat and identify device infections. Heart Rhythm, 2007, 4, 1467-1470.	0.7	49

#	ARTICLE	IF	CITATIONS
235	Lead failures: Dealing with even less perfect. Heart Rhythm, 2007, 4, 897-899.	0.7	27
236	The Benefits of Biventricular Pacing in Heart Failure Patients with Narrow QRS, NYHA Class II and Right Ventricular Pacing. PACE - Pacing and Clinical Electrophysiology, 2007, 30, 193-198.	1.2	10
237	Use of an Intracardiac Electrogram Eliminates the Need for a Surface ECG during Implantable Cardioverter-Defibrillator Follow-Up. PACE - Pacing and Clinical Electrophysiology, 2007, 30, 1432-1437.	1.2	7
238	Dynamic obstruction to coronary sinus access: The Thebesian valve. Heart Rhythm, 2006, 3, 1240-1241.	0.7	30
239	Recommendations from the Heart Rhythm Society Task Force on Device Performance Policies and Guidelines Endorsed by the American College of Cardiology Foundation (ACCF) and the American Heart Association (AHA) and the International Coalition of Pacing and Electrophysiology Organizations (COPE). Heart Rhythm, 2006, 3, 1250-1273.	0.7	160
240	A Comparison of Empiric to Physician-Tailored Programming of Implantable Cardioverter-Defibrillators. Journal of the American College of Cardiology, 2006, 48, 330-339.	2.8	225
241	I Design of the Primary Prevention Parameters Evaluation (PREPARE) trial of implantable cardioverter defibrillators to reduce patient morbidity [NCT00279279]. Trials, 2006, 7, 18.	1.6	12
242	Group Purchasing Organizations: Optimizing Cardiac Device Selection, Therapy Delivery, and Fiscal Responsibility. PACE - Pacing and Clinical Electrophysiology, 2006, 29, 1404-1409.	1.2	0
243	Tissue Synchronization Imaging and Optimal Left Ventricular Pacing Site in Cardiac Resynchronization Therapy. American Journal of Cardiology, 2006, 97, 1615-1621.	1.6	181
244	Usefulness of Atrioventricular Delay Optimization Using Doppler Assessment of Mitral Inflow in Patients Undergoing Cardiac Resynchronization Therapy. American Journal of Cardiology, 2006, 98, 780-785.	1.6	93
245	Dual-Chamber Versus Single-Chamber Detection Enhancements for Implantable Defibrillator Rhythm Diagnosis. Circulation, 2006, 113, 2871-2879.	1.6	245
246	Pacemaker and ICD Malfunction—An Incomplete Picture. JAMA - Journal of the American Medical Association, 2006, 295, 1944.	7.4	23
247	Complications of Pacemakers and Defibrillators in the Elderly. The American Journal of Geriatric Cardiology, 2006, 15, 102-107.	0.6	44
248	The Role of Swab and Tissue Culture in the Diagnosis of Implantable Cardiac Device Infection. PACE - Pacing and Clinical Electrophysiology, 2005, 28, 1276-1281.	1.2	122
249	Outcome of Magnetic Resonance Imaging (MRI) in Selected Patients with Implantable Cardioverter Defibrillators (ICDs). PACE - Pacing and Clinical Electrophysiology, 2005, 28, 270-273.	1.2	92
250	The Impact of Povidone-Iodine Pocket Irrigation Use on Pacemaker and Defibrillator Infections. PACE - Pacing and Clinical Electrophysiology, 2005, 28, 789-794.	1.2	44
251	Strategies for the Safe Magnetic Resonance Imaging of Pacemaker-Dependent Patients. PACE - Pacing and Clinical Electrophysiology, 2005, 28, 1041-1046.	1.2	65
252	Delayed Lead Perforation: A Disturbing Trend. PACE - Pacing and Clinical Electrophysiology, 2005, 28, 251-253.	1.2	181

#	ARTICLE	IF	CITATIONS
253	Improved Extraction of ePTFE and Medical Adhesive Modified Defibrillation Leads from the Coronary Sinus and Great Cardiac Vein. PACE - Pacing and Clinical Electrophysiology, 2005, 28, 205-211.	1.2	44
254	ICDs: Dealing with Less Than Perfect. Journal of Cardiovascular Electrophysiology, 2005, 16, 796-797.	1.7	14
255	Safe Scanning, but Frequent Artifacts Mimicking Bradycardia and Tachycardia During Magnetic Resonance Imaging (MRI) in Patients with an Implantable Loop Recorder (ILR). Annals of Noninvasive Electrocardiology, 2005, 10, 404-408.	1.1	41
256	A Comparison of the AVID and DAVID Trials of Implantable Defibrillators. American Journal of Cardiology, 2005, 95, 1431-1435.	1.6	6
257	Optimal Combination of Discriminators for Differentiating Ventricular from Supraventricular Tachycardia by Dual-Chamber Defibrillators. Journal of Cardiovascular Electrophysiology, 2005, 16, 732-739.	1.7	65
258	Safe, sensible, sagacious: responsible scanning of pacemaker patients. European Heart Journal, 2005, 26, 1683-1684.	2.2	17
259	Giant Flow Reversal in Pulmonary Venous Flow as a Possible Mechanism for Asynchronous Pacing-induced Heart Failure. Journal of the American Society of Echocardiography, 2005, 18, 722-728.	2.8	14
260	Minimally Invasive Left Ventricular Epicardial Lead Placement: Surgical Techniques for Heart Failure Resynchronization Therapy. Annals of Thoracic Surgery, 2005, 79, 1536-1544.	1.3	97
261	Electrical Conduction Disturbance Effects on Dynamic Changes of Functional Mitral Regurgitation. Journal of the American College of Cardiology, 2005, 46, 2270-2276.	2.8	28
262	Safety and efficacy of radiofrequency energy catheter ablation of atrial fibrillation in patients with pacemakers and implantable cardiac defibrillators. Heart Rhythm, 2005, 2, 1309-1316.	0.7	38
263	Combined Minimally Invasive Pulmonary Vein Isolation, Left Atrial Appendage Excision and Cardiac Resynchronization Therapy for Heart Failure: Case Report. Heart Surgery Forum, 2005, 8, E249-E252.	0.5	11
264	Diagnosis of Sleep-Related Breathing Disorders by Visual Analysis of Transthoracic Impedance Signals in Pacemakers. Circulation, 2004, 110, 2562-2567.	1.6	36
265	Remote Interrogation and Monitoring of Implantable Cardioverter Defibrillators. Journal of Interventional Cardiac Electrophysiology, 2004, 11, 161-166.	1.3	80
266	A trial design for evaluation of empiric programming of implantable cardioverter defibrillators to improve patient management. Current Controlled Trials in Cardiovascular Medicine, 2004, 5, 12.	1.5	11
267	Differences in Tachyarrhythmia Detection and Implantable Cardioverter Defibrillator Therapy by Primary or Secondary Prevention Indication in Cardiac Resynchronization Therapy Patients. Journal of Cardiovascular Electrophysiology, 2004, 15, 1002-1009.	1.7	260
268	Azygos Vein Lead Implantation: A Novel Adjunctive Technique for Implantable Cardioverter Defibrillator Placement. Journal of Cardiovascular Electrophysiology, 2004, 15, 780-783.	1.7	51
269	Impact of Coronary Sinus Lead Position on Biventricular Pacing: Journal of Cardiovascular Electrophysiology, 2004, 15, 1120-1125.	1.7	158
270	Lead-Induced Venous Thrombosis: Journal of Cardiovascular Electrophysiology, 2004, 15, 1263-1264.	1.7	8

#	ARTICLE	IF	CITATIONS
271	Intravascular pacemaker and defibrillator lead extraction: A state-of-the-art review. Heart Rhythm, 2004, 1, 739-745.	0.7	69
272	Evaluation of ventricular synchrony using novel Doppler echocardiographic indices in patients with heart failure receiving cardiac resynchronization therapy. Journal of the American Society of Echocardiography, 2004, 17, 845-850.	2.8	40
273	Implantable Cardioverter-Defibrillator: Technical Aspects. , 2004, , 970-979.		3
274	The Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial: Rationale, Design, Results, Clinical Implications and Lessons for Future Trials. Journal of Interventional Cardiac Electrophysiology, 2003, 7, 468-472.	1.0	42
275	Comparison of arrhythmia recurrence in patients presenting with ventricular fibrillation versus ventricular tachycardia in the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial. American Journal of Cardiology, 2003, 91, 812-816.	1.6	31
276	Complications arising after implantation of DDD pacemakers: the MOST experience. American Journal of Cardiology, 2003, 92, 740-741.	1.6	175
277	QRS duration and prediction of mortality in patients undergoing risk stratification for ventricular arrhythmias. American Journal of Cardiology, 2003, 92, 798-803.	1.6	63
278	Analysis of Implantable Cardioverter Defibrillator Therapy in the Antiarrhythmics Versus Implantable Defibrillators (AVID) Trial. Journal of Cardiovascular Electrophysiology, 2003, 14, 940-948.	1.7	160
279	Right Ventricular Outflow Versus Apical Pacing in Pacemaker Patients with Congestive Heart Failure and Atrial Fibrillation. Journal of Cardiovascular Electrophysiology, 2003, 14, 1180-1186.	1.7	204
280	North American Society of Pacing and Electrophysiology. PACE - Pacing and Clinical Electrophysiology, 2003, 26, 127-131.	1.2	23
281	Nonthoracotomy Implantable Defibrillator Lead Extraction:. Results and Comparison with Extraction of Pacemaker Leads. PACE - Pacing and Clinical Electrophysiology, 2003, 26, 1944-1950.	1.2	53
282	The Strength-Duration Relationship of Monophasic Waveforms with Varying Capacitance Sizes in External Defibrillation. PACE - Pacing and Clinical Electrophysiology, 2003, 26, 2213-2218.	1.2	2
283	Combined Cardiac Resynchronization and Implantable Cardioversion Defibrillation in Advanced Chronic Heart Failure. JAMA - Journal of the American Medical Association, 2003, 289, 2685.	7.4	1,446
284	Pacemaker Therapy for Prevention of Syncope in Patients With Recurrent Severe Vasovagal Syncope. JAMA - Journal of the American Medical Association, 2003, 289, 2224.	7.4	453
285	Dual-Chamber Pacing or Ventricular Backup Pacing in Patients With an Implantable Defibrillator. JAMA - Journal of the American Medical Association, 2002, 288, 3115.	7.4	1,799
286	Health values before and after pacemaker implantation. American Heart Journal, 2002, 144, 687-692.	2.7	28
287	Frequency and associations of symptomatic deterioration after dual-chamber defibrillator implantation in patients with ischemic or idiopathic dilated cardiomyopathy. American Journal of Cardiology, 2002, 90, 79-82.	1.6	30
288	Current status and future expectations for multisite pacing in heart failure. Current Cardiology Reports, 2002, 4, 238-247.	2.9	1

#	ARTICLE	IF	CITATIONS
289	Noninvasive Assessment of Cardiac Resynchronization Therapy for Congestive Heart Failure Using Myocardial Strain and Left Ventricular Peak Power as Parameters of Myocardial Synchrony and Function. Journal of Cardiovascular Electrophysiology, 2002, 13, 1203-1208.	1.7	61
290	Experience with a Dual Chamber Implantable Defibrillator. PACE - Pacing and Clinical Electrophysiology, 2002, 25, 1041-1048.	1.2	19
291	Matching Approved "Nondedicated" Hardware to Obtain Biventricular Pacing and Defibrillation: Feasibility and Troubleshooting. PACE - Pacing and Clinical Electrophysiology, 2002, 25, 1066-1071.	1.2	19
292	Percutaneous Treatment for Pacemaker-Associated Superior Vena Cava Syndrome. PACE - Pacing and Clinical Electrophysiology, 2002, 25, 1628-1633.	1.2	44
293	Rate Responsive Pacing Using Transthoracic Impedance Minute Ventilation Sensors: A Multicenter Study on Calibration Stability. PACE - Pacing and Clinical Electrophysiology, 2002, 25, 1679-1684.	1.2	11
294	Clinical Study of the Laser Sheath for Lead Extraction: The Total Experience in the United States. PACE - Pacing and Clinical Electrophysiology, 2002, 25, 804-808.	1.2	283
295	Lead- and device-related complications in the Antiarrhythmics Versus Implantable Defibrillators Trial. American Heart Journal, 2001, 141, 92-98.	2.7	145
296	The management of surgical complications of pacemaker and implantable cardioverter-defibrillators. Current Opinion in Cardiology, 2001, 16, 66-71.	1.8	94
297	Bradyarrhythmias. Current Treatment Options in Cardiovascular Medicine, 2001, 3, 291-298.	0.9	9
298	Should all patients receive dual chamber pacing ICDs? The rationale for the DAVID trial. , 2001, 2, 215.		11
299	Correlation of Impedance Minute Ventilation with Measured Minute Ventilation in a Rate Responsive Pacemaker. PACE - Pacing and Clinical Electrophysiology, 2001, 24, 989-993.	1.2	21
300	Assessment of Pacemaker Chronotropic Response: Implementation of the Wilkoff Mathematical Model. PACE - Pacing and Clinical Electrophysiology, 2001, 24, 1748-1754.	1.2	34
301	Biodegradation of polyether polyurethane inner insulation in bipolar pacemaker leads. Journal of Biomedical Materials Research Part B, 2001, 58, 302-307.	3.1	146
302	Critical Analysis of Dual-Chamber Implantable Cardioverter-Defibrillator Arrhythmia Detection. Circulation, 2001, 103, 381-386.	1.6	176
303	Biodegradation of polyether polyurethane inner insulation in bipolar pacemaker leads. Journal of Biomedical Materials Research Part B, 2001, 58, 302-307.	3.1	1
304	Influence of Posture, Breathing Pattern, and Type of Exercise on Minute Ventilation Estimation by a Pacemaker Transthoracic Impedance Sensor. PACE - Pacing and Clinical Electrophysiology, 2000, 23, 1767-1771.	1.2	16
305	Recommendations for Extraction of Chronically Implanted Transvenous Pacing and Defibrillator Leads: Indications, Facilities, Training. PACE - Pacing and Clinical Electrophysiology, 2000, 23, 544-551.	1.2	263
306	Voltage Dependence of ICD Lead Polarization and the Effect of Iridium Oxide Coating. PACE - Pacing and Clinical Electrophysiology, 2000, 23, 818-823.	1.2	2

#	ARTICLE	IF	CITATIONS
307	Cardiac lead extraction with a novel locking stylet. Journal of Interventional Cardiac Electrophysiology, 2000, 4, 591-593.	1.3	25
308	Initial Experience With Larger Laser Sheaths for the Removal of Transvenous Pacemaker and Implantable Defibrillator Leads. Circulation, 1999, 100, 516-525.	1.6	121
309	Intravascular Extraction of Problematic or Infected Permanent Pacemaker Leads: 1994-1996. PACE - Pacing and Clinical Electrophysiology, 1999, 22, 1348-1357.	1.2	246
310	Biventricular Shocking Leads Improve Defibrillation Efficacy. Journal of Cardiovascular Electrophysiology, 1999, 10, 561-565.	1.7	2
311	Transiliac permanent pacemaker implantation after extraction of infected pectoral pacemaker systems. American Journal of Cardiology, 1999, 84, 474-475.	1.6	18
312	Pacemaker lead extraction with the laser sheath: results of the pacing lead extraction with the excimer sheath (PLEXES) trial ¹¹ No financial support was received for performing the procedures or collecting the data, or for data analysis.. Journal of the American College of Cardiology, 1999, 33, 1671-1676.	2.8	416
313	The Ablate and Pace Trial: a prospective study of catheter ablation of the AV conduction system and permanent pacemaker implantation for treatment of atrial fibrillation. APT Investigators. Journal of Interventional Cardiac Electrophysiology, 1998, 2, 121-135.	1.3	264
314	Effects of Respiration Phase on Ventricular Defibrillation Threshold in a Hot Can Electrode System. PACE - Pacing and Clinical Electrophysiology, 1998, 21, 1216-1224.	1.2	2
315	Optimal Small-Capacitor Biphasic Waveform for External Defibrillation. Circulation, 1998, 98, 2487-2493.	1.6	22
316	Quality of Life and Clinical Outcomes in Elderly Patients Treated with Ventricular Pacing as Compared with Dual-Chamber Pacing. New England Journal of Medicine, 1998, 338, 1097-1104.	27.0	584
317	Optimized First Phase Tilt in "Parallel-Series" Biphasic Waveform. Journal of Cardiovascular Electrophysiology, 1997, 8, 649-657.	1.7	11
318	Effects of Polarity on Defibrillation Thresholds Using a Biphasic Waveform in a Hot Can Electrode System. PACE - Pacing and Clinical Electrophysiology, 1997, 20, 2911-2916.	1.2	8
319	Sawtooth First Phase Biphasic Defibrillation Waveform.. Journal of Cardiovascular Electrophysiology, 1997, 8, 517-528.	1.7	14
320	Additional Lead Improves Defibrillation Efficacy With an Abdominal "Hot Can"™ Electrode System. Circulation, 1997, 96, 4400-4407.	1.6	10
321	Safe Performance of Magnetic Resonance Imaging on Five Patients with Permanent Cardiac Pacemakers. PACE - Pacing and Clinical Electrophysiology, 1996, 19, 913-919.	1.2	141
322	Personal and Public Safety Issues Related to Arrhythmias That May Affect Consciousness: Implications for Regulation and Physician Recommendations. Circulation, 1996, 94, 1147-1166.	1.6	179
323	Large Change in Voltage at Phase Reversal Improves Biphasic Defibrillation Thresholds. Circulation, 1996, 94, 1768-1773.	1.6	19
324	Adequacy of implantable cardioverter-defibrillator lead placement for tachyarrhythmia detection by sinus rhythm electrogram amplitude. American Journal of Cardiology, 1995, 76, 1162-1166.	1.6	19

#	ARTICLE	IF	CITATIONS
325	Description and Evaluation of the Res-QTM Arrhythmia Control Device. Journal of Cardiovascular Electrophysiology, 1995, 6, 147-161.	1.7	1
326	Low Incidence of Lead Related Complications Associated with Nonthoracotomy Implantable Cardioverter Defibrillator Systems. PACE - Pacing and Clinical Electrophysiology, 1995, 18, 172-178.	1.2	59
327	Five-Years Experience with Intravascular Lead Extraction. PACE - Pacing and Clinical Electrophysiology, 1994, 17, 2016-2020.	1.2	267
328	Long-Term Performance of Epimyocardial Pacing Leads in Adults: Comparison with Endocardial Leads. PACE - Pacing and Clinical Electrophysiology, 1993, 16, 412-417.	1.2	11
329	Exercise Testing for Chronotropic Assessment. Cardiology Clinics, 1992, 10, 705-717.	2.2	175
330	Pacing Lead Survival: Performance of Different Models. PACE - Pacing and Clinical Electrophysiology, 1992, 15, 1991-1995.	1.2	29
331	Criteria for Optimal Pacemaker Function. Journal of Cardiovascular Electrophysiology, 1991, 2, 416-418.	1.7	4
332	DDIR Versus VVIR Pacing in Patients with Paroxysmal Atrial Tachyarrhythmias. PACE - Pacing and Clinical Electrophysiology, 1991, 14, 1630-1638.	1.2	11
333	Early Clinical Experience with a Minute Ventilation Sensor DDDR Pacemaker. PACE - Pacing and Clinical Electrophysiology, 1991, 14, 1815-1820.	1.2	16
334	Six-Year Clinical Experience with the Automatic Implantable Cardioverter Defibrillator. PACE - Pacing and Clinical Electrophysiology, 1991, 14, 1850-1854.	1.2	24
335	Clinical Performance of the Implantable Cardioverter Defibrillator: Electrocardiographic Documentation of 101 Spontaneous Discharges. PACE - Pacing and Clinical Electrophysiology, 1991, 14, 280-285.	1.2	71
336	Successful Percutaneous Extraction of a Chronic Left Ventricular Pacing Lead. PACE - Pacing and Clinical Electrophysiology, 1991, 14, 1448-1451.	1.2	40
337	Chronotropic Response to Exercise in Patients with Atrial Fibrillation. PACE - Pacing and Clinical Electrophysiology, 1990, 13, 179-187.	1.2	51
338	The Effects of Percutaneous Catheter Ablation on Preexisting Permanent Pacemakers. PACE - Pacing and Clinical Electrophysiology, 1990, 13, 1637-1645.	1.2	20
339	Intravascular Lead Extraction Using Locking Stylets, Sheaths, and Other Techniques. PACE - Pacing and Clinical Electrophysiology, 1990, 13, 1864-1870.	1.2	87
340	Clinical Experience with the Combination of an Antitachycardia Pacemaker (Orthocor II) and the Implantable Cardioverter-Defibrillator in Drug-Refractory Ventricular Tachycardia. Journal of Interventional Cardiology, 1990, 3, 269-276.	1.2	0
341	The Use of Beep-O-Grams in the Assessment of Automatic Implantable Cardioverter Defibrillator Sensing Function. PACE - Pacing and Clinical Electrophysiology, 1989, 12, 1737-1745.	1.2	25
342	Continuous Right Ventricular Volume Assessment by Catheter Measurement of Impedance for Antitachycardia System Control. PACE - Pacing and Clinical Electrophysiology, 1989, 12, 1918-1926.	1.2	35

#	ARTICLE	IF	CITATIONS
343	A Mathematical Model of the Cardiac Chronotropic Response to Exercise. Journal of Electrophysiology, 1989, 3, 176-180.	0.5	144
344	Effect of Implantable Defibrillator Patch Electrodes on Left Ventricular Filling. Journal of Interventional Cardiology, 1989, 2, 161-166.	1.2	2
345	Effects of Extracorporeal Shock Wave Lithotripsy on Cardiac Pacemakers and its Safety in Patients with Implanted Cardiac Pacemakers. PACE - Pacing and Clinical Electrophysiology, 1988, 11, 1607-1616.	1.2	48
346	Current Concepts in Intravascular Pacemaker and Defibrillator Lead Extraction. , 0, , 124-133.		2
347	ICD Lead Extraction: When, Why and How?. , 0, , 327-334.		1